St. Jude Children’s Research Hospital shared a post on LinkedIn:
“St. Jude scientists have introduced CHANGE-seq-BE, a novel method for evaluating the specificity and activity of genome base editors. This technology detects subtle off-target effects that traditional genome editing safety tools often miss, addressing a critical challenge in the field. It offers an unbiased, sensitive and resource-efficient solution, advancing both fundamental and clinical research in genome editing.
Unlike conventional approaches that require expensive whole genome sequencing or rely on pre-selected targets, CHANGE-seq-BE uses a streamlined process to identify off-target edits across the entire genome. In direct comparisons, it detected nearly all off-target sites found by other methods, as well as many additional sites that competing techniques missed, while using only a fraction of the sequencing resources required by traditional methods.
“We’ve enabled those developing these therapies to quickly understand and find the base editors with the highest potential activity and specificity,” Shengdar Q. Tsai, PhD, St. Jude Department of Hematology, said. “We hope that methods like CHANGE-seq-BE will open the door toward more genome editing therapies being developed for and reaching the patients who need them.”
As genome editing technologies advance, tools such as CHANGE-seq-BE will be essential to ensure safety and efficacy. St. Jude continues to integrate this method into clinical trials and fundamental research, helping to accelerate the development of precise genome editing therapies for patients.”
More posts featuring St. Jude Children’s Research Hospital on OncoDaily.